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Summary Background: We started a large multicenter pros-
pective follow-up study to provide reliable risk estimates of
venous thrombosis in families with various thrombophilic
defects.Objectives: This paper describes data collected at study
entry on venous events experienced before study inclusion, i.e.
the baseline data. Patients/methods: All individuals (probands,
relatives) registered in nine European thrombosis centers with
the factor (F)V Leiden mutation, a deﬁciency of antithrombin,
protein C or protein S, or a combination of these defects, were
enrolled between March 1994 and September 1997. As control
individuals, partners, friends or acquaintances of the thrombo-
philic participants were included. Incidence and relative risk of
objectively conﬁrmedvenous thrombotic events (VTEs) prior to
entry were calculated for the relatives with thrombophilia and
the controls. Results: Of the 846 relatives with thrombophilia
(excluding probands), 139 (16%) had experienced a VTE with
an incidence of 4.4 per 1000 person years. Of the controls, 15 of
the 1212 (1%) controls had experienced a VTE with an
incidence of 0.3 per 1000 person years. The risk of venous
thrombosis associated with familial thrombophilia was 15.7
(95% CI 9.2–26.8) and remained similar after adjustment for
regional and sex-eﬀects (16.4; 95% CI 9.6–28.0). The highest
incidence per 1000 person years was found in relatives with
combined defects (8.4; 95% CI 5.6–12.2), and the lowest
incidence was found in those with the FVLeidenmutation (1.5;
95% CI 0.8–2.6). Conclusions: Considerable diﬀerences in the
lifetime risk of VTE were observed among individuals with
diﬀerent thrombophilia defects.
Keywords: genetic risk factors, thrombophilia, venous throm-
bosis.
Introduction
In developed countries, venous thrombosis occurs in 1–2 per
1000 individuals per year [1,2] and commonlymanifests as deep
vein thrombosis (DVT), with or without pulmonary embolism
(PE) [3]. Major complications in the clinical course of DVT are
death from PE, development of a disabling post–thrombotic
syndrome and recurrences [2,4–6]. Predisposing factors for
venous thrombosis can be genetic or acquired, or both, and
may lead to a life-long or temporary increase in the tendency to
venous thrombosis (thrombophilia) [7]. As the clinical expres-
sion varies between individuals who are heterozygous for the
same genetic thrombotic defect, as shown within genotypically
identical family members [8], venous thrombosis is believed to
be a multicausal disease [9,10]. The hypothesis of multicausal
pathogenesis is underlined by the ﬁnding that the risk of venous
thrombosis is higher in families with inherited thrombophilia
than in individuals with the same defect without a positive
family history [11,12]. This difference probably is the result of
interaction within these families of the inherited defect with
other genetic or acquired risk factors [11–13]. Several hered-
itary prothrombotic defects have been identiﬁed in the last four
decades. The ﬁrst was antithrombin deﬁciency, identiﬁed in
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1965 [14]. Since then, several other hereditary defects have been
identiﬁed as risk factors for venous thrombosis, such as protein
C deﬁciency, protein S deﬁciency, factor (F)V Leiden and
prothrombin 20210A [15–18].
Rational guidelines for optimal treatment policies in families
with inherited thrombophilia are lacking due to few available
studies of sufﬁcient size. Therefore, we started a large
multicenter prospective follow-up study to determine the
natural history of venous thrombosis in family members of
symptomatic patients with at least one inherited prothrombotic
defect. With these risk estimates guidelines may be inferred for
treatment and prevention of venous thrombosis in families with
different kinds of inherited thrombophilia. Other endpoints
such as arterial thrombotic disease (myocardial infarction [MI],
stroke), death from various causes, major haemorrhage and
fetal loss were also studied. The European Prospective Cohort
on Thrombophilia (EPCOT) study combines data on individ-
uals with familial thrombophilia over a large geographical area
of eight European nations and therefore is the largest cohort of
individuals with inherited thrombophilia, thus providing reli-
able risk estimates.
This paper will describe the data collected at study entry on
the occurence of venous thrombosis in the EPCOT participants
prior to entry, i.e. the baseline data on the history of venous
thrombosis.
Study design
Participants and methods
A total of nine centers (Barcelona, Bologna, Frankfurt,
Glasgow, Leiden, Malmo¨, Paris, Shefﬁeld and Vienna) with
long-standing interest in thrombophilia research from eight
countries participated in the EPCOT-study. We included
patients referred to these specialist clinics to create a large
cohort of individuals with deﬁciencies in natural anticoagu-
lants, which are rare, and to address the risk of venous
thrombosis found in thrombophilic families compared with
patients with a similar thrombophilia defect without a family
history. Each center enrolled all registered probands (ﬁrst of a
family in whom thrombophilia was detected) with a deﬁciency
of antithrombin, protein C or protein S, or FV Leiden, who
had at least one relative with the same familial defect, and their
registered relatives. Fewer individuals with FV Leiden were
included than would be expected based on the frequency of this
mutation; however, the FV Leiden mutation was identiﬁed
more recently than the other defects of which carriers were
collected over the past 15 years. As controls, partners or, if
there were none, friends or acquaintances of the thrombophilic
participants were included. Controls were excluded if they were
known to have heritable thrombophilia or if they were related
to a participant with an inherited thrombotic defect. There
were no exclusion criteria for individuals with inherited
thrombophilia: we included those who were symptomatic as
well as those who were asymptomatic, and those who received
anticoagulant treatment as well as those who did not. The
study was approved by the LeidenUniversity HospitalMedical
Ethics Committee, and all participants in this study gave their
informed consent.
Data collection
Inclusion took place betweenMarch 1994 and September 1997
with most of the participants (84% of controls and 88% of
thrombophilic individuals) included in 1994 and 1995. Infor-
mation was collected at inclusion, and annually during the
prospective follow-upbystandardizeddata collection forms.All
data were collected by the responsible physician or another
health professional at the participating centers by consulting
another physician, by medical chart review or by telephone or
mail contact with the patient. Completed formswere sent to the
coordinating center with only the patient identiﬁers code to
protect patient conﬁdentiality. Data collected at study entry
included information on general demographics, defect details
(type, subtype, diagnostic methods, genetic conﬁrmation),
personal history with regard to thrombosis (dates, location,
diagnostic test results), currentmedication (oral anticoagulants,
oral contraceptives, hormone replacement therapy or other
medication), other risk factors (e.g. obesity, varicose veins),
obstetric history and family history of thrombosis. Data
collection was identical for controls and thrombophilic individ-
uals, except for items on the type and subtype of thrombophilia.
All centres performed the various assays according to their
local protocol and participated in an external quality assess-
ment scheme for thrombophilia testing. For the ﬁrst 2 years
this was the quality assurance scheme developed for the
European Concerted Action on Thrombosis (ECAT/EQAS)
(Leiden, the Netherlands) and for the subsequent years, the
UK NEQAS quality assurance scheme (Shefﬁeld, UK).
Diagnostic criteria were based on those used in these centers,
which for the deﬁciencies was based on repeated testing, and in
some cases also on genotypic conﬁrmation.
Recruitment was before identiﬁcation of the G20210A
mutation in the prothrombin gene. During prospective fol-
low-up, we gathered information on the presence of this
mutation as a second defect for 504 relatives and 424 probands
included in the analyzes. Thus we only have information on the
prothrombin G20210A mutation as a second defect in 64% of
the participants with inherited thrombophilia.
Analysis and statistics
For the analysis of the baseline data collected at study inclusion
on the history of venous thrombotic events prior to study entry,
we included only probands and relatives from families in which
thrombophilia testing was done because of the occurrence of
venous thrombosis in the proband or family, and not when this
was done solely for research purposes or family planning. This
restriction was to avoid selection bias and to stay as close as
possible to the real-life situation of an individual from a
symptomatic thrombophilia family asking a physician for
advice.
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We were interested in the number, type, age at onset, event-
free survival, incidence, and relative risk of venous thrombo-
embolic events (VTEs) experienced before inclusion in the
study. Only objectively conﬁrmed events (by ultrasound,
Duplex or venography for DVT, and by ventilation-perfusion
scanning or angiography for PE) and conﬁrmed events at other
locations were counted as such; non-deﬁnite events, i.e. based
on clinical or patient diagnosis were recorded but not
considered in the analysis reported here, including superﬁcial
thrombophlebitis. Spontaneous venous thrombosis was de-
ﬁned as venous thrombosis without known precipitating risk
factors (hospital admission, surgery, immobilization, plaster
cast, uninterrupted travels over 8 h, pregnancy, delivery).
Thrombotic events in which the only risk factor was use of oral
contraceptives were also labeled as spontaneous.
As probands were selected on having had venous thrombo-
sis, we determined only the number and type of events, the age
of onset and the age at which 50% of the probands had
experienced venous thrombosis (median survival) prior to
study entry. The probability of being free of events at any given
age was analyzed by constructing Kaplan–Meier life tables.
From these survival analyses we estimated the cumulative
incidence of thrombosis with conﬁdence intervals at age 30, 45
and 60.
The incidence of venous thrombotic events in relatives and
controls was calculated by dividing the number of events by the
total of observation years, i.e. the time between birth and the
ﬁrst event of interest, or until the end of study, i.e. the inclusion
in the EPCOT study without a history of DVT, PE or other
major event. The 95% conﬁdence intervals (CIs) were calcu-
lated according to a Poisson distribution for the number of
events [19]. Hazard ratios as an estimation of the relative risk
were calculated by Cox-regression, with thrombosis as the
dependent variable and presence of thrombophilia as an
independent variable. Center (as stratum) and sex (as categor-
ical variable) were entered in the Cox-regression model to
adjust for regional and sex effects. Event-free survival,
incidence and hazard ratios were calculated regardless of
previous manifestations of superﬁcial thrombophlebitis.
Results
A total of 2838 participants were enrolled in the cohort of
whom 1626 had a thrombophilic defect (672 probands, 954
relatives of probands) and 1212 were controls (900 partners,
312 friends). In total, 600 probands and 846 relatives met the
criteria that they were initially investigated because of
thrombosis themselves or because of thrombosis in a family
member.
The main characteristics at inclusion of probands, relatives
and controls are depicted in Table 1. Among individuals with
thrombophilia, men were slightly underrepresented (40% in
probands and relatives). At study entry, 19 (10%) of the
protein C deﬁcient relatives, 43 (22%) of the protein S
deﬁciency relatives, 32 (22%) of the antithrombin deﬁcient
relatives, 11 (5%) of the relatives with factor V Leiden and
22 (23%) of the relatives with combined defects received life-
long anticoagulation.
Thrombotic history
Probands Of all included probands, 532 (89%) had experi-
enced an objectively conﬁrmed venous thrombosis prior to
study entry (Table 2). The remaining 68 probands (11%) had
been identiﬁed because of superﬁcial thrombophlebitis (n ¼
58), or were the ﬁrst in the family in whom a defect was
demonstrated with no personal but only a family history of
venous thrombosis (n ¼ 10). Of all probands with a personal
history of thrombosis, 288 (54%) had experienced one or more
recurrencies before study entry. The mean age at the ﬁrst
venous thrombosis was 30 years (range 0–71) and ranged per
type of defect from 26 years in patients with antithrombin
deﬁciency to 33 years in patients with FV Leiden (Table 2). Of
all probands, 50% had experienced venous thrombosis before
the age of 29 (Fig. 1). Spontaneous venous thrombotic events,
i.e. venous events without known precipitating risk factors or
during use of oral contraceptives only, occurred in 220 of the
362 (61%) probands for whom this information was available.
Table 1 General characteristics of the probands, relatives and controls at
baseline
Thrombophilic
individuals
ControlsProbands Relatives
All (n) 600 846 1212
Men (n) 237 339 627
Women (n) 363 507 585
PC deﬁciency (n) 126a 188 N/A
PS deﬁciency (n) 93 193 N/A
AT deﬁciency (n)* 102 145 N/A
FVL (n) 175b 225c N/A
Combined defects (n) 104 95 N/A
PC deﬁciency-PS deﬁciency (n) 2 2 N/A
FVL-PC deﬁciency (n) 22d 22 N/A
FVL-PS deﬁciency (n) 23d 24 N/A
FVL-AT deﬁciency (n) 11 9 N/A
PT20210A-PC deﬁciency (n) 11 12 N/A
PT20210A-PS deﬁciency (n) 8 6e N/A
PT20210A-AT deﬁciency (n) 5 6 N/A
PT20210A-FVL (n) 19f 13g N/A
PT20210A-FVL-PC deﬁciency (n) 2 1 N/A
PT20210A-FVL-PS deﬁciency (n) 1 0 N/A
Age at inclusion (mean (range)) 41 (2–78) 39 (0–91) 42 (3–87)
< 18 years old (n) 5 73 36
18–45 years old (n) 355 470 695
> 45 years old (n) 240 303 481
Abbreviation: PC ¼ protein C, PS ¼ protein S, AT ¼ antithrombin,
FVL ¼ factor V Leiden, PT20210A ¼ prothrombin G20210A, N/A ¼
not applicable.
a2 were homozygous; b31 were homozygous; c13 were homozygous; d1
was homozygous for FVL; e1 was homozygous for PT20210A; f4 were
homozygous for FVL; g1 was homozygous for FVL and 1 was
homozygous for PT20210A.
*Six probands and 14 relatives showed only low antithrombin activity,
2 relatives were identiﬁed by DNA-testing only, and 5 probands and 7
relatives had only activity levels measured.
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Relatives and controls Of all included relatives, 139 (16%)
had experienced an objectively conﬁrmed venous thrombosis
compared with 15 (1%) in the controls (Table 2) prior to study
entry. The percentage of relatives with a venous event varied
per type of defect from 6% in those with the FV Leiden
mutation to 29% in individuals with combined defects
(Table 3). Recurrencies were present before baseline in 58
(42%) relatives with a history of venous thrombosis, and in
only 2 (13%) of the controls with a history of venous
thrombosis.
The mean age at the ﬁrst venous thrombosis before study
entry was 36 years (range 13–71) in the relatives and 41 years
(range 24–68) in the controls (Table 2). Per type of defect, the
age of onset ranged from 28 years in relatives with combined
defects to 42 years in relatives with protein C deﬁciency
(Table 2).
Spontaneous venous events occured before study entry in 54
of the 90 (60%) relatives and in 7 of the 14 (50%) controls for
whom this information was available, with thrombotic events
occuring during use of oral contraceptives considered as
spontaneous events.
The incidence of venous events experienced before study
entry in relatives was 4.4 (95% CI 3.7–5.2) per 1000 person
years and in controls 0.3 (95% CI 0.2–0.5) per 1000 person
years (Table 3). Per type of thrombophilia, the incidence
was lowest in the relatives with the FV Leiden mutation (1.5
per 1000 person years) and highest for those with combined
defects (8.4 per 1000 person years) (Table 3). The incidence
regarding FV Leiden did not change after exclusion of
homozygous individuals. The incidence was higher in men
in the relatives (6.2 per 1000 person years for men and 3.2
per 1000 person years for women), but similar for both
men and women in the controls (0.3 per 1000 person years
for men and 0.2 per 1000 person years for women)
(Table 3).
The probability of being free of venous events before study
entry in the thrombophilic individuals (probands excluded) was
91% (95% CI 89–93%) at age 30, 82% (95% CI 79–86%) at
age 45 and 70% (95% CI 65–76%) at age 60 (Fig. 1). Per type
of defect, the probability of being free of venous events at age
45 was 87% with protein C deﬁciency, 74% with protein S
deﬁciency, 80% with antithrombin deﬁciency, 94% with FV
Leiden and 67% with combined defects. In the controls, the
probability of being free of venous thrombosis at age 30, 45 and
60 was, respectively, 100%, 99% (95% CI 98–100%) and 98%
(95% CI 97–99%) (Fig. 1).
The risk of venous thrombosis derived from the incidences
of venous events experienced before study entry was 16 times
higher in the relatives with thrombophilia compared with the
controls (relative risk of 15.7; 95% CI 9.2–26.8) and
remained similar after adjustment for center and sex (relative
risk of 16.4; 95% CI 9.6–28.0) (Table 4). Per type of
thrombophilia the relative risk differed greatly: the highest
risk was found in the relatives with combined defects. For
the relatives with single defects, the risk was highest in
relatives with protein S deﬁciency (32.4; 95% CI 16.7–62.9)
and lowest in the relatives with the FV Leiden mutation (4.3;
95% CI 1.9–9.7) (Table 4). Exclusion of homozygous
individuals with the FV Leiden mutation did not affect
these estimates. The relative risk was higher in men than in
women: 18.1 (95% CI 9.0–36.3) and 13.9 (95% CI 6.0–32.4),
respectively (Table 4).
Table 2 Description of objectively conﬁrmed venous events before study
entry
Thrombophilic
individuals
Controls
(n ¼ 1212)
Probands
(n ¼ 600)
Relatives
(n ¼ 846)
Individuals with venous
events before baseline (n)
532 139 15
DVT (n) 359 89 9
PE (n) 154 45 3
Other VT (n) 19 5 3
PC deﬁciency (n) 110 22 N/A
PS deﬁciency (n) 84 50 N/A
AT deﬁciency (n) 90 25 N/A
FVL (n) 152a 14b N/A
Combined defects (n) 96c 28 N/A
Age at onset all major
events (mean (range))
30 (0–71) 36 (13–71) 41 (24–68)
PC deﬁciency 32 (11–71) 42 (23–71) N/A
PS deﬁciency 29 (2–68) 37 (13–71) N/A
AT deﬁciency 26 (0–53) 34 (17–64) N/A
FVL 33 (14–68) 38 (17–61) N/A
Combined defects 28 (3–69) 28 (13–59) N/A
Abbreviations: DVT: deep venous thrombosis; PE: pulmonary
embolism with or without DVT; VT: venous thrombosis; PC: protein
C; PS: protein S; AT: antithrombin; FVL: FV Leiden; N/A: not
applicable.
a30 were homozygous; b2 were homozygous; c6 were homozygous for
FVL.
Age at onset (yrs)
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Fig. 1. Venous event-free survival of the probands (solid line), relatives
(short dashed line) and controls (long dashed line) until study entry.
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Discussion
To obtain reliable estimates of the risk of venous thrombosis
associated with familial thrombophilia caused by various
defects, we started a prospective collaborative multinational
study including 1626 individuals with inherited thrombophilia
and 1212 controls from eight European countries.
Data collected at study entry on the history of venous
thrombosis prior to study inclusion showed a 16 times
increased risk of VTEs for the individuals with inherited
thrombophilia (only relatives of probands included) compared
with the normal population (crude relative risk of 15.7 (95%CI
9.2–26.8), adjusted relative risk of 16.4 (95% CI 9.6 –28.0)
adjusted for sex and regional effects). The incidence of venous
events before study entry was 4.4 per 1000 person years in the
relatives, compared with 0.3 per 1000 person years in the
controls.
The highest incidence of events and the lowest age at onset
before study entry were found in the relatives with combined
defects (8.4 per 1000 person years; mean age at onset 28 years),
as has been described by other authors [11,20–25], For single
defects we found the highest risk with protein S deﬁciency (7.1
per 1000 person years), and the lowest for FV Leiden (1.5 per
1000 person years). Although there is one report that protein S
deﬁciency confers the highest risk of VTE [26], several others
have shown that the greatest venous thromboembolic risk is
associated with antithrombin deﬁciency [23,24,27,28]. Whether
there are real differences in the venous thrombotic risk in
respect of antithrombin and protein S deﬁciency remains
unresolved. The absence of a difference in our study might
reﬂect differences in the distribution of, yet unknown, inter-
acting second defects or the presence of the prothrombin
G20210A mutation for which 36% of the participants could
not be tested. It is, however, noteworthy, that a population
study, in which selection or referral bias was excluded, also did
not ﬁnd a higher risk for antithrombin deﬁciency [29]. Another
possible explanation for these conﬂicting results is that since
antithrombin deﬁciency was the ﬁrst thrombophilia to be
discovered, affected individuals could have received prophy-
laxis more frequently than individuals with other types
of thrombophilia. However, when the year of diagnosis
of thrombophilia was taken as follow-up end-point instead of
the age at which individuals were without venous events at
study entry, the incidence was only slightly higher for
individuals with antithrombin deﬁciency: 5.9% (95% CI 3.8–
8.7).
Table 3 Incidence per 1000 person years of venous events before study entry in the controls and the relatives
All
(n)
Events
(n (%))
Person years
(years)
Incidence
(per 1000 years (95% CI))
Controls 1212 15 (1) 51079 0.3 (0.2–0.5)
Men 627 9 (1) 26746 0.3 (0.2–0.6)
Women 585 6 (1) 24333 0.2 (0.1–0.5)
Age at inclusion >18 years* 1171 15 (1) 29504 0.5 (0.3–0.8)
Age at inclusion >45 years** 477 6 (1) 5712 1.1 (0.4–2.3)
Relatives 846 139 (16) 31660 4.4 (3.7–5.2)
PC deﬁciency 188 22 (12) 7059 3.1 (2.0–4.7)
PS deﬁciency 193 50 (26) 7059 7.1 (5.3–9.3)
AT deﬁciency 145 25 (17) 5034 5.0 (3.2–7.3)
FVL 225 14 (6) 9186 1.5 (0.8–2.6)
Combined defects 95 28 (29) 3322 8.4 (5.6–12.2)
Men 339 78 (23) 12634 6.2 (4.9–7.7)
Women 507 61 (12) 19026 3.2 (2.5–4.1)
Age at inclusion >18 years* 743 126 (17) 16893 7.5 (6.2–8.9)
Age at inclusion >45 years** 260 39 (15) 3593 10.9 (7.7–14.8)
Abbreviations: PC ¼ protein C, PS ¼ protein S, AT ¼ antithrombin, FVL ¼ FV Leiden, CI ¼ conﬁdence interval.
*Only person years above 18 years were counted. Individuals older than 18 years at baseline who had events before age 18 were excluded.
**Only person years above 45 years were counted. Individuals older than 45 years at baseline who had events before age 45 were excluded.
Table 4 Relative risk of venous events before study entry in the relatives
Crude relative
risk*
Adjusted**
relative risk
All relatives vs. controls 15.7 (9.2–26.8) 16.4 (9.6–28.0)
PC deﬁciency 11.1 (5.7–21.4) 11.3 (5.7–22.3)
PS deﬁciency 26.1 (14.7–46.5) 32.4 (16.7–62.9)
AT deﬁciency 19.0 (10.0–36.1) 17.5 (9.1–33.8)
FVL 5.2 (2.5–10.8) 4.3 (1.9–9.7)
Combined defects 32.0 (17.1–60.0) 46.7 (22.5–97.1)
Men 19.2 (9.6–38.4) 18.1 (9.0–36.3)
Women 13.8 (5.9–31.8) 13.9 (6.0–32.4)
Age at inclusion >18 years 14.4 (8.4–24.6) 14.4 (8.4–24.6)
Age at inclusion >45 years 10.2 (4.3–24.0) 10.3 (4.3–24.4)
Abbreviations: PC ¼ protein C, PS ¼ protein S, AT ¼ antithrombin,
FVL ¼ FV Leiden.
*For every defect, we compared relatives with the defect with all
controls.
**Adjusted for regional and sex-eﬀects. For the relative risk per sex,
the relative risk was only adjusted for regional eﬀects.
Only person years above 18 years were counted. Individuals older
than 18 years at baseline who had events before age 18 were excluded.
Only person years above 45 years were counted. Individuals older
than 45 years at baseline who had events before age 45 were excluded.
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The annual risk of thrombophilia-associated venous
thrombosis before study entry was sex-dependent: the inci-
dence was higher in male relatives than in female relatives,
but similar for both male and female controls. As many
venous thrombotic events in young women can be attributed
to oral contraception, the low percentage of asymptomatic
thrombophilic women using oral contraceptives (16%; age
15–35) compared with asymptomatic female controls (37%;
age 15–35) offers a likely explanation for a lower risk in
women with thrombophilia compared with control women.
Another explanation is that female relatives were referred to
a thrombosis clinic for investigation before hormone pre-
scription or pregnancy, whereas men were only referred when
they were symptomatic.
Labelling events as provoked or unprovoked is difﬁcult and
mostly dependent on the researcher’s deﬁnition of a provoked
event, e.g. we labeled events occuring during oral contraceptive
use as unprovoked, as oral contraceptive use is a generally
weak and very common risk factor during which anticoagu-
lation treatment is mostly not considered. Studies including
detailed, reliable information on risk factors could give insight
in the risk of venous thrombosis associated with these risk
factors.
We have included over 1500 individuals with familial
thrombophilia from eight European countries, so our study
yields reliable and generalizable results. It should be noted,
however, that in this study follow-up was counted only for
those entered in the cohort, i.e. individuals with any of these
defects who died before the start of the study were not
included. This implies that we may have underestimated the
risk of thrombosis. However, in previous studies we have
shown that the mortality of antithrombin deﬁciency [30],
protein C deﬁciency [31] and FV leiden [32] does not exceed
the population risk. We also only counted objectively
conﬁrmed manifestations of venous thrombosis to avoid
selection bias, which means that we may have excluded
inadequately diagnosed or missed events, and thus could have
underestimated the risk. However, only a fraction of all
reported events were not objectively conﬁrmed. We also did
not have full details on thromboprophylaxis prior to recruit-
ment. The incidence of VTEs may thus have been reduced in
the relatives if short-term thromboprophylaxis was used to
cover surgery, trauma or pregnancy. After diagnosis of a
hereditary thrombotic defect, thromboprophylaxis may be
more likely to be offered even to asymptomatic relatives and
oral contraception with estrogen-containing preparations is
discouraged at least in some countries. However, incidences
per defect were only slightly higher or remained similar to the
incidences shown in Table 3 when the year of diagnosis of
thrombophilia was taken as the study end-point instead of the
age at which individuals were without venous events at study
entry. The risk of venous thrombosis might have been
overestimated when mostly symptomatic relatives were
referred to a thrombosis clinic for investigation. In addition,
the risk for individuals with single defects might have been
overestimated when they were carriers of the prothrombin
G20210A mutation but could not be tested for this particular
mutation in our study.
It is important to note that our results concern individuals
from thrombophilic families registered at specialized clinics,
and hence the results may be generalized to such individuals,
but not to unselected individuals with the same defect, as we
have previously shown that these individuals have a lower risk
of thrombosis [11,12].
While more detailed data will result from the prospective
follow-up, this study showed that individuals with familial
thrombophilia have an increased risk of venous thrombosis
with a high risk of spontaneous thrombosis and recurrencies.
Since 70% of the individuals with thrombophilic defects were
free of thrombosis at age 60, it is unlikely that long-term
anticoagulation started at a young age would have beneﬁts
outweighing the risks of this treatment especially in those with a
single genetic prothrombotic defect.
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